WO1999066909A3 - Procede et compositions pour le traitement ou l'amelioration des dysfonctionnements sexuels de la femme - Google Patents
Procede et compositions pour le traitement ou l'amelioration des dysfonctionnements sexuels de la femme Download PDFInfo
- Publication number
- WO1999066909A3 WO1999066909A3 PCT/CA1999/000567 CA9900567W WO9966909A3 WO 1999066909 A3 WO1999066909 A3 WO 1999066909A3 CA 9900567 W CA9900567 W CA 9900567W WO 9966909 A3 WO9966909 A3 WO 9966909A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- apomorphine
- vaginal
- hydroxytryptamine
- diminished
- sexual dysfunction
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 206010057671 Female sexual dysfunction Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229960004046 apomorphine Drugs 0.000 abstract 3
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 abstract 3
- 230000003292 diminished effect Effects 0.000 abstract 3
- JTEJPPKMYBDEMY-UHFFFAOYSA-N 5-methoxytryptamine Chemical compound COC1=CC=C2NC=C(CCN)C2=C1 JTEJPPKMYBDEMY-UHFFFAOYSA-N 0.000 abstract 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- -1 methergolide Chemical compound 0.000 abstract 2
- SILDPWPVKZETMP-AMUMSSSMSA-N (2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S,3S)-1-[(2-amino-2-oxoethyl)amino]-3-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O SILDPWPVKZETMP-AMUMSSSMSA-N 0.000 abstract 1
- XMINXPSYULINQV-XPLLYYSMSA-N (2s)-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-13-[(2s)-butan-2-yl]-10-(hydroxymethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-n-[(2s,3s)-1-[(2-amino-2-oxoethyl)amino]-3-m Chemical compound NC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1 XMINXPSYULINQV-XPLLYYSMSA-N 0.000 abstract 1
- OAQPLDRHJAFJSE-YXEOJCNXSA-N (2s)-2-[[(2s)-1-[(2r)-2-[[(2s)-4-amino-2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]-3-sulfanylpropanoyl]pyrrolidine-2- Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(N)=O)NC(=O)[C@@H](N)CS)C1=CC=C(O)C=C1 OAQPLDRHJAFJSE-YXEOJCNXSA-N 0.000 abstract 1
- ABKBWHGCQCOZPM-YHDADAAYSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-16-benzyl-13-[(2s)-butan-2-yl]-10-[3-(diaminomethylideneamino)propyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos Chemical compound C([C@H]1C(=O)NC(C(N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 ABKBWHGCQCOZPM-YHDADAAYSA-N 0.000 abstract 1
- RSMWPLBUPINXDV-UHFFFAOYSA-N 1-(4-iodo-2,5-dimethoxyphenyl)propan-1-amine Chemical compound CCC(N)C1=CC(OC)=C(I)C=C1OC RSMWPLBUPINXDV-UHFFFAOYSA-N 0.000 abstract 1
- DAHCMEORVXDYEP-UHFFFAOYSA-N 1-[19-amino-7,10-bis(2-amino-2-oxoethyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-n-[1-[(2-amino-2-oxoethyl)amino]-3-methyl-1-oxobutan-2-yl]pyrrolidine-2-carboxamide Chemical compound NC(=O)CNC(=O)C(C(C)C)NC(=O)C1CCCN1C(=O)C1NC(=O)C(CC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CC=2C=CC=CC=2)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(N)CSSC1 DAHCMEORVXDYEP-UHFFFAOYSA-N 0.000 abstract 1
- GUXCJKRYHLCHKV-UHFFFAOYSA-N 1-[19-amino-7,10-bis(2-amino-2-oxoethyl)-13-butan-2-yl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-n-[1-[(2-amino-2-oxoethyl)amino]-3-methyl-1-oxobutan-2-yl]pyrrolidine-2-carboxamide Chemical compound N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(C(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 GUXCJKRYHLCHKV-UHFFFAOYSA-N 0.000 abstract 1
- WYWNEDARFVJQSG-UHFFFAOYSA-N 2-methylserotonin Chemical compound C1=C(O)C=C2C(CCN)=C(C)NC2=C1 WYWNEDARFVJQSG-UHFFFAOYSA-N 0.000 abstract 1
- 229940097276 5-methoxytryptamine Drugs 0.000 abstract 1
- 101800004868 Conopressin-G Proteins 0.000 abstract 1
- 208000004483 Dyspareunia Diseases 0.000 abstract 1
- 101800000805 Isotocin Proteins 0.000 abstract 1
- 101800004705 Mesotocin Proteins 0.000 abstract 1
- MVAWJSIDNICKHF-UHFFFAOYSA-N N-acetylserotonin Chemical compound C1=C(O)C=C2C(CCNC(=O)C)=CNC2=C1 MVAWJSIDNICKHF-UHFFFAOYSA-N 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 abstract 1
- MAOSLUBGVKVOCE-UHFFFAOYSA-N Seritocin Natural products CCC(C)C(NC(=O)C1CCCN1C(=O)C(CS)NC(=O)C(CO)NC(=O)C(CCC(=O)N)NC(=O)C(NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(N)CS)C(C)CC)C(=O)NCC(=O)N MAOSLUBGVKVOCE-UHFFFAOYSA-N 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 101710117812 Valitocin Proteins 0.000 abstract 1
- 206010069055 Vulvovaginal pain Diseases 0.000 abstract 1
- LYPCGXKCQDYTFV-UHFFFAOYSA-N alpha-methylserotonin Chemical compound C1=C(O)C=C2C(CC(N)C)=CNC2=C1 LYPCGXKCQDYTFV-UHFFFAOYSA-N 0.000 abstract 1
- 239000003098 androgen Substances 0.000 abstract 1
- 108700022601 asvatocin Proteins 0.000 abstract 1
- VWXRQYYUEIYXCZ-OBIMUBPZSA-N atosiban Chemical compound C1=CC(OCC)=CC=C1C[C@@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)CSSCCC(=O)N1 VWXRQYYUEIYXCZ-OBIMUBPZSA-N 0.000 abstract 1
- 229960002403 atosiban Drugs 0.000 abstract 1
- 229960002802 bromocriptine Drugs 0.000 abstract 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 abstract 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 abstract 1
- 229960002495 buspirone Drugs 0.000 abstract 1
- 108700021293 carbetocin Proteins 0.000 abstract 1
- NSTRIRCPWQHTIA-DTRKZRJBSA-N carbetocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSCCCC(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(OC)C=C1 NSTRIRCPWQHTIA-DTRKZRJBSA-N 0.000 abstract 1
- 229960001118 carbetocin Drugs 0.000 abstract 1
- 108700027018 deaminooxytocin Proteins 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- GTYWGUNQAMYZPF-QPLNMOKZSA-N demoxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 GTYWGUNQAMYZPF-QPLNMOKZSA-N 0.000 abstract 1
- 229960000477 demoxytocin Drugs 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 108700043517 glumitocin Proteins 0.000 abstract 1
- 229960003587 lisuride Drugs 0.000 abstract 1
- 238000005461 lubrication Methods 0.000 abstract 1
- 229960004851 pergolide Drugs 0.000 abstract 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 abstract 1
- 108700022597 phasvatocin Proteins 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000035807 sensation Effects 0.000 abstract 1
- 108700017270 seritocin Proteins 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 abstract 1
- 229960003708 sumatriptan Drugs 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 229960003604 testosterone Drugs 0.000 abstract 1
- 230000000982 vasogenic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention porte sur un procédé de traitement des dysfonctionnements sexuels de la femme dont: les symptômes vasculogènes d'un engorgement vaginal retardé, une lubrification réduite du vagin, des rapports douloureux ou désagréables (dyspareunie), des sensations vaginales réduites, un orgasme vaginal atténué, des sensations clitoridiennes réduites, un orgasme clitoridien atténué, et de combat des douleurs vaginales, en stimulant la libération d'oxyde d'azote par le nerf pelvien périphérique. Le procédé consiste à administrer à la femme le nécessitant une dose à effet thérapeutique d'un composé agissant sur une voie mésencéphalique pour accroître le flux sanguin dans le lit vasculaire des artères iliaques, hypogastriques, et honteuses et stimuler la libération de NO par les cellules des nerfs NANC périphériques. Le composé préféré à cette fin est l'apomorphine ou l'un de ses sels, esters ou précurseurs pharmacocompatibles. Il est également possible d'associer l'apomorphine à une quantité potentialisante d'androgène, de préférence de testostérone, prise soit avant, soit avec l'apomorphine.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU42547/99A AU4254799A (en) | 1998-06-22 | 1999-06-21 | Method and compositions for the treatment or amelioration of female sexual dysfunction |
| JP2000555595A JP2002518435A (ja) | 1998-06-22 | 1999-06-21 | 女性の性機能不全の治療または改善のための方法および組成物 |
| MXPA01000275A MXPA01000275A (es) | 1998-06-22 | 1999-06-21 | Metodo y composiciones para el tratamiento o alivio de disfunciones sexuales femeninas. |
| CA002334550A CA2334550A1 (fr) | 1998-06-22 | 1999-06-21 | Procede et compositions pour le traitement ou l'amelioration des dysfonctionnements sexuels de la femme |
| EP99957146A EP1089736A2 (fr) | 1998-06-22 | 1999-06-21 | Procede et compositions pour le traitement ou l'amelioration des dysfonctionnements sexuels de la femme |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10298798A | 1998-06-22 | 1998-06-22 | |
| US09/102,987 | 1998-06-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1999066909A2 WO1999066909A2 (fr) | 1999-12-29 |
| WO1999066909A3 true WO1999066909A3 (fr) | 2000-06-29 |
Family
ID=22292763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CA1999/000567 WO1999066909A2 (fr) | 1998-06-22 | 1999-06-21 | Procede et compositions pour le traitement ou l'amelioration des dysfonctionnements sexuels de la femme |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1089736A2 (fr) |
| JP (1) | JP2002518435A (fr) |
| AR (1) | AR019694A1 (fr) |
| AU (1) | AU4254799A (fr) |
| CA (1) | CA2334550A1 (fr) |
| MX (1) | MXPA01000275A (fr) |
| WO (1) | WO1999066909A2 (fr) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9125816B2 (en) | 2000-08-30 | 2015-09-08 | Besins Healthcare Inc. | Pharmaceutical composition and method for treating hypogonadism |
| US12433904B2 (en) | 2019-04-17 | 2025-10-07 | Compass Pathfinder Limited | Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0005797A (pt) * | 2000-03-20 | 2001-10-16 | Abbott Lab | Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados |
| HUP0301773A3 (en) * | 2000-04-07 | 2006-02-28 | Tap Pharmaceutical Prod Inc | Apomorphine derivatives and methods for their use |
| FI20002756A0 (fi) * | 2000-12-15 | 2000-12-15 | Orion Yhtymae Oyj | Uusi hoitomenetelmä |
| IL157734A0 (en) | 2001-03-06 | 2004-03-28 | Cellegy Pharma Inc | Pharmaceutical compositions for the treatment of urogenital disorders |
| US20030022875A1 (en) * | 2001-07-27 | 2003-01-30 | Wilson Leland F. | As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness |
| GB0204919D0 (en) * | 2002-03-01 | 2002-04-17 | Cst Medical Ltd | Treatment of female sexual dysfunction |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4521421A (en) * | 1983-09-26 | 1985-06-04 | Eli Lilly And Company | Treatment of sexual dysfunction |
| EP0172697A2 (fr) * | 1984-08-02 | 1986-02-26 | Eli Lilly And Company | Octahydro-oxazolo[4,5-g]quinoléines |
| WO1987004621A1 (fr) * | 1986-02-04 | 1987-08-13 | Ekkehard Othmer | Traitement du dysfonctionnement sexuel avec de la buspirone |
| WO1993023035A2 (fr) * | 1992-05-18 | 1993-11-25 | Smithkline Beecham Plc | Emploi de derives d'indolone dans le traitement de troubles de la memoire, du dysfonctionnement sexuel et de la maladie de parkinson |
| US5945117A (en) * | 1998-01-30 | 1999-08-31 | Pentech Pharmaceuticals, Inc. | Treatment of female sexual dysfunction |
-
1999
- 1999-06-21 MX MXPA01000275A patent/MXPA01000275A/es unknown
- 1999-06-21 CA CA002334550A patent/CA2334550A1/fr not_active Abandoned
- 1999-06-21 AU AU42547/99A patent/AU4254799A/en not_active Abandoned
- 1999-06-21 JP JP2000555595A patent/JP2002518435A/ja active Pending
- 1999-06-21 EP EP99957146A patent/EP1089736A2/fr not_active Withdrawn
- 1999-06-21 WO PCT/CA1999/000567 patent/WO1999066909A2/fr not_active Application Discontinuation
- 1999-06-22 AR ARP990102966A patent/AR019694A1/es unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4521421A (en) * | 1983-09-26 | 1985-06-04 | Eli Lilly And Company | Treatment of sexual dysfunction |
| EP0172697A2 (fr) * | 1984-08-02 | 1986-02-26 | Eli Lilly And Company | Octahydro-oxazolo[4,5-g]quinoléines |
| WO1987004621A1 (fr) * | 1986-02-04 | 1987-08-13 | Ekkehard Othmer | Traitement du dysfonctionnement sexuel avec de la buspirone |
| WO1993023035A2 (fr) * | 1992-05-18 | 1993-11-25 | Smithkline Beecham Plc | Emploi de derives d'indolone dans le traitement de troubles de la memoire, du dysfonctionnement sexuel et de la maladie de parkinson |
| US5945117A (en) * | 1998-01-30 | 1999-08-31 | Pentech Pharmaceuticals, Inc. | Treatment of female sexual dysfunction |
Non-Patent Citations (5)
| Title |
|---|
| FERRARI, F. ET AL: "Influence of apomorphine on rat female sexual behavior and its relation with induction of stereotypy", RIV. FARMACOL. TER. (1977), 8(4), 355-63, XP002121202 * |
| GOLDSTEIN I. ET AL: "Vasculogenic female sexual dysfunction: Vaginal engorgement and clitoral erectile insufficiency syndromes.", INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, (1998) 10/SUPPL. 2 (S84-S90)., XP002121200 * |
| HAMBURGER-BAR, R.; RIGTER, H.: "Apomorphine: Facilitation of sexual behaviour in female rats", EUROPEAN JOURNAL OF PHARMACOLOGY, XP002121204 * |
| MELIS M.R. ET AL: "Dopamine and sexual behavior.", NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, (1995) 19/1 (19-38)., XP002121203 * |
| SEGRAVES R.T. ET AL: "Pharmacotherapy for sexual disorders: Advantages and pitfalls.", SEXUAL AND MARITAL THERAPY, (1998) 13/3 (295-309)., XP002121201 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9125816B2 (en) | 2000-08-30 | 2015-09-08 | Besins Healthcare Inc. | Pharmaceutical composition and method for treating hypogonadism |
| US9132089B2 (en) | 2000-08-30 | 2015-09-15 | Besins Healthcare Inc. | Pharmaceutical composition and method for treating hypogonadism |
| US12433904B2 (en) | 2019-04-17 | 2025-10-07 | Compass Pathfinder Limited | Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
Also Published As
| Publication number | Publication date |
|---|---|
| AR019694A1 (es) | 2002-03-13 |
| AU4254799A (en) | 2000-01-10 |
| WO1999066909A2 (fr) | 1999-12-29 |
| MXPA01000275A (es) | 2002-04-24 |
| EP1089736A2 (fr) | 2001-04-11 |
| JP2002518435A (ja) | 2002-06-25 |
| CA2334550A1 (fr) | 1999-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20010924A1 (es) | Compuestos inhibidores de fosfodiesterasa utiles para el tratamiento de la disfuncion sexual femenina | |
| MXPA00007447A (es) | Tratamiento de disfuncion sexual femenina. | |
| MY158162A (en) | 5-membered heterocycle-based p38 kinase inhibitors | |
| WO2002051420A3 (fr) | Techniques et formulations pour le traitement de dysfonctionnements sexuels chez la femme | |
| WO1999066909A3 (fr) | Procede et compositions pour le traitement ou l'amelioration des dysfonctionnements sexuels de la femme | |
| MY136841A (en) | Carbamate-substituted pyrazolopyridines | |
| CA2383785A1 (fr) | Techniques d'utilisation d'inhibiteurs selectifs de recaptage de serotonine a apparition rapide pour traiter un dysfonctionnement sexuel | |
| IL157320A0 (en) | Rapid-onset medicament for the treatment of sexual dysfunction | |
| WO2005013914A8 (fr) | Compositions utilisees comme inhibiteurs de canaux sodium voltage dependants | |
| MXPA05003104A (es) | Hidromorfonas n-sustituidas y uso de las mismas. | |
| BG105664A (en) | Use of apomophines for the treatment of organic erectile dysfunction in males | |
| WO2001000221A3 (fr) | Methodes therapeutiques et compositions pour le traitement de troubles interpersonnels et du comportement | |
| IN2005KO00312A (fr) | ||
| AU2003274476A1 (en) | Treatment of female sexual dysfunction | |
| EP1108426A3 (fr) | Utilisation d'agonistes des prostaglandines pour traiter les troubles de l'érection et l'impotence | |
| AU764009B2 (en) | Methods for the normalization of sexual response and amelioration of long term genital tissue degradation | |
| WO2002041894A3 (fr) | Utilisation d'agonistes selectifs des recepteur d4 de la dopamine dans le traitement de dysfonctions sexuelles | |
| MXPA03005437A (es) | Derivados substituidos de pirazino quinoxalina como agonistas y antagonistas del receptor de serotonina. | |
| SE0200475D0 (sv) | Oral farmaceutisk beredning | |
| WO1999065475A3 (fr) | Combinaison de phentolamine et apomorphine pour le traitement concernant les fonctions et les dysfonctionnements sexuels | |
| WO2001000196A3 (fr) | Mirtazapine destinee a la prise de poids dans les maladies cachectisantes | |
| MY134074A (en) | Pharmaceutical composition comprising gamma-butyrobetaine for treatment of impotence | |
| AU8906201A (en) | Methods and compositions for the treatment and prevention of sexual dysfunction | |
| AU2024223859A1 (en) | Compositions and methods of treating female sexual dysfunction and female sexual arousal disorder | |
| TW200621231A (en) | Therapeutic combinations comprising a selective estrogen receptor modulator and a selective androgen receptor modulator |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| ENP | Entry into the national phase |
Ref document number: 2334550 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/000275 Country of ref document: MX |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 42547/99 Country of ref document: AU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1999957146 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1999957146 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| NENP | Non-entry into the national phase |
Ref country code: CA |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1999957146 Country of ref document: EP |